Susanna Moberly, APRN
Rheumatology · Nicholasville, KYNPI 1568843316
Payments from drug & device makers
What this record shows
15 manufacturers reported payments, led by AbbVie at 58.8% of the total. 2025 is the largest year on record at $2,132, more than ten times the $47 reported in 2021.
Across 74 payments — averaging $48.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$348
- Mallinckrodt Hospital Products Inc.$272
- Novartis$197
- Amgen$162
- UCB, Inc.$106
- plus $395 from 9 others
What the payments were for
- Speaking & faculty fees$1,65046%
- Food & beverage$1,94054%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $2,111 |
| Johnson & Johnson | 10 | $348 |
| Mallinckrodt Hospital Products Inc. | 7 | $272 |
| Novartis | 8 | $197 |
| Amgen | 7 | $162 |
| UCB, Inc. | 4 | $106 |
| Pfizer | 4 | $73 |
| Lilly USA, LLC | 3 | $70 |
| Sandoz | 3 | $69 |
| Boehringer Ingelheim | 3 | $68 |
| Sobi, Inc | 1 | $25 |
| Sanofi | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Aurinia Pharma U.S., Inc. | 1 | $21 |
| AstraZeneca | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,590 in reported general payments places this provider in the 60th percentile of 81 rheumatology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 130 | $842,505 |
| Enbrel SureclickEtanercept | 106 | $784,520 |
| Humira(Cf) PenAdalimumab | 95 | $736,576 |
| Skyrizi PenRisankizumab-Rzaa | 22 | $479,621 |
| OtezlaApremilast | 49 | $238,217 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 20 | $223,008 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 31 | $221,660 |
| Cimzia (2 Pack)Certolizumab Pegol | 26 | $218,063 |
| TremfyaGuselkumab | 11 | $153,213 |
| Xeljanz XrTofacitinib Citrate | 21 | $124,303 |
| Cosentyx Unoready PenSecukinumab | 12 | $112,020 |
| SimponiGolimumab | 11 | $78,809 |
| Humira PenAdalimumab | 12 | $75,542 |
| OlumiantBaricitinib | 22 | $59,542 |
| KevzaraSarilumab | 13 | $55,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Savella | $2,111 | $863,615145 claims |
| AmgenOtezla | $162 | $238,21749 claims |
| Johnson & JohnsonTremfya, Simponi | $348 | $232,02222 claims |
| PfizerOctagam | $73 | $223,00820 claims |
| UCB, Inc.Cimzia (2 Pack) | $106 | $218,06326 claims |
| Lilly USA, LLCOlumiant | $70 | $59,54222 claims |
| SanofiKevzara | $25 | $55,33113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 81 rheumatology providers in Kentucky.
Other rheumatology in Nicholasville
- Asad FraserBowling Green$355K
- Rebecca CallisFlorence$272K
- Gary CrumpLouisville$176K
- Benjamin BooneLouisville$80K
- Jacquelyn SmithLouisville$63K
- Neha PansuriaBowling Green$39K
- Timothy LoneskySomerset$32K
- Mansoor AhmedRichmond$29K
- Liza VargheseCrestview Hills$29K
- Lisa JuneLouisville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.